We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Bioassay Test Helps Diagnose Graves' Disease

By LabMedica International staff writers
Posted on 15 Sep 2009
Print article
A new blood testing method specifically detects thyroid-stimulating immunoglobulins (TSIs), used to help identify Graves' disease.

The Thyretain TSI Reporter bioassay provides laboratories with the ability to test for TSI in the bloodstream using standard laboratory equipment, and unlike other nonspecific thyroid-related assays, does not require the use of radioactivity, and also eliminates ambiguity of test results that can be confounded by the presence of non-TSI autoantibodies. The kit includes a genetically engineered cell line that produces the reporter enzyme luciferase in response to specific TSI binding, and the amount of luciferase produced is then rapidly detected using a luminometer. The bioassay offers greater specificity because it only detects the TSI present in a patient's serum, aiding in a more accurate early diagnosis of Graves' disease. The Thyretain TSI Reporter bioassay was developed by Diagnostic Hybrids (Athens, OH, USA), and has been approved by the U.S. Food and Drug Administration (FDA).

"When used earlier when hyperthyroidism is first suspected, this assay may provide primary care physicians and patients alike reliable diagnostic information when classic symptoms of goiter or thyroid-related eye disease [ophthalmopathy] are absent,” said Jeff Houtz, senior product manager for Thyretain at Diagnostic Hybrids.

"Initial symptoms for thyroid disorders can often be nonspecific. By finding TSIs in patient serum, Thyretain is a rapid and reliable bioassay that provides a definitive assessment that could lead to earlier diagnosis of Graves' disease and better patient management,” said Frank Schwartz, M.D., a professor of endocrinology at the Ohio University College of Osteopathic Medicine (Northfield, USA).

Graves' disease is an autoimmune disease that most commonly affects the thyroid, frequently causing it to enlarge to twice its size or more (goiter) and become overactive, causing overstimulation of the thyroid gland and low thyroid-stimulating hormone (TSH) levels, a condition known as hyperthyroidism. Related symptoms such include increased heartbeat, muscle weakness, disturbed sleep, and irritability. It can also affect the eyes, causing bulging eyes (exophthalmos). It affects other systems of the body, including the skin, heart, circulation, and nervous system. Eighty percent of Graves' disease cases occur in women, and can be difficult to diagnose since symptoms vary greatly and often mimic other illnesses.

Related Links:

Diagnostic Hybrids

Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
PSA Test
Humasis PSA Card
New
Silver Member
H-FABP Assay
Heart-Type Fatty Acid-Binding Protein Assay

Print article

Channels

Clinical Chemistry

view channel
Image: A one-step confirmatory laboratory test could definitively diagnose active syphilis infection within 10 minutes (Photo courtesy of Adobe Stock)

First Comprehensive Syphilis Test to Definitively Diagnose Active Infection In 10 Minutes

In the United States, syphilis cases have surged by nearly 80% from 2018 to 2023, with 209,253 cases recorded in the most recent year of data. Syphilis, which can be transmitted sexually or from mother... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.